The Cerebellar-Glutamate Connection in Autism: A Wiring-Level Hypothesis
Part 1 examined autism as a brain-energy disorder — a fuel problem. Part 2 examined the immune-mediated subset — an antibody problem. This part examines a third, distinct possibility: that a part of autism reflects a wiring-level difference in the cerebellum and in glutamatergic circuits — the brain’s excitatory pathways.
This is not an energy problem, and it is not an immune problem. It is a structural and functional difference in how certain brain circuits are built and how they signal.
The series separates what we know from what our research adds. Here, a well-established neuropathological observation is that cerebellar Purkinje cell loss appears in autism — a finding replicated across multiple post-mortem studies (reported as background in our research (Maccallini 2026)). What our research adds is the reading that a cerebellar glutamatergic genetic signal — present in genome-wide data (Maccallini 2026) — may connect that neuropathology to sensory hypersensitivity. That reading is a registered speculation, not an established finding.
1 The cerebellum is more than motor control
For decades the cerebellum was understood as a motor-coordination structure. A now-extensive literature places it in cognition, affect, and sensory processing as well — the “cerebellar cognitive-affective syndrome.”
The relevance to autism is direct: cerebellar Purkinje cell loss is among the most replicated neuropathological findings in autism. Purkinje cells are the cerebellum’s output neurons, and their vulnerability appears central to the condition.
4 The testable prediction
This hypothesis is falsifiable, and the prediction is specific:
A cerebellar cell-type polygenic risk score (derived from the genetic enrichment data) will correlate with Sensory Profile questionnaire scores — especially auditory and tactile sensitivity — in autism cohorts, and will be elevated in people with co-occurring autistic traits.
If true, sensory sensitivity would be traceable to a specific, genetically measurable wiring difference — not a vague “overall sensitivity,” but a cerebellar glutamatergic signal that can be quantified in an individual’s genome.
5 The honest limits
This is a speculative hypothesis, with explicit low confidence — a registered speculation, not an established finding.
- The Purkinje-cell finding is replicated neuropathology, but the link to the genetic signal is an inference.
- The cerebellar and glutamatergic enrichment comes from gene-set analysis, which is sensitive to analytic choices and can be biased toward long, conserved genes.
- The glutamatergic signal is one contributing reading of otherwise-disconnected phenomena — it does not resolve them alone.
- Sensory sensitivity is multiply determined; even if the cerebellar prediction holds, it is one of several contributing mechanisms.
The prediction is testable now, with existing genetic data and existing questionnaires. It has not yet been run.
6 What to take away
The cerebellar-glutamate model offers a wiring-level explanation for a core autism symptom — sensory sensitivity — that is neither a fuel problem nor an immune problem. It is a developmental difference in how excitatory circuits are built.
Unlike Parts 1 and 2, this strand has no direct treatment implication yet. It is not “modifiable” in the same sense as iron or BH4, and it is not an antibody target. Its value is explanatory and diagnostic: it points to a specific, genetically measurable signature of sensory sensitivity.
The encouraging part: the prediction is cheap and testable with existing data. If it holds, it gives autism’s sensory experience a concrete biological anchor. If it fails, it narrows the search.
This is Part 3 of a four-part series on the biology of autism. Part 1 covers the brain-energy model and the multi-pathway treatment hypothesis. Part 2 covers the immune-mediated subset. Part 4 asks when autism-like features are acquired and reversible.
This article reflects a registered research hypothesis with low confidence, not established clinical fact.